Up­dat­ed: Eu­ro­pean reg­u­la­tors in­ves­ti­gat­ing 150 re­ports of self-in­jury, sui­cide risk in pa­tients tak­ing No­vo Nordisk meds for weight loss

The Eu­ro­pean Med­i­cines Agency is look­ing in­to about 150 re­ports of “pos­si­ble cas­es of self-in­jury and sui­ci­dal thoughts” for weight loss pa­tients who used No­vo Nordisk’s semaglu­tide or li­raglu­tide med­i­cines.

The first three case re­ports were flagged by mem­ber agency Ice­landic Med­i­cines Agency, un­veiled on Mon­day. The EMA’s safe­ty com­mit­tee, the Phar­ma­covig­i­lance Risk As­sess­ment Com­mit­tee (PRAC), is now in­ves­ti­gat­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER